How can we improve the treatment of bone metastases further?

Current Opinion in Oncology

Volumn 10, Issue SUPPL. 1, 1998, Pages

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

BONE METASTASIS; BONE PAIN; BREAST CANCER; CONFERENCE PAPER; HUMAN; MORBIDITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; ESTROGEN ANTAGONISTS; FEMALE; FORECASTING; HUMANS; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOISOTOPE TELETHERAPY; RANDOMIZED CONTROLLED TRIALS; SAMARIUM;

EID: 0031756228     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Rubens RD, Coleman RE: Bone metastases. In: Clinical Oncology. Edited by Abeloff MD, Armitage JO, Lichter AS, Niederhuber J. New York: Churchill Livingstone; 1995:643-665.
2. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335:1785-1791.
3. Lipton A, Theriault R, Leff R, Gluck S, Stewart J, et al.: Long term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia™) infusions [abstract]. Am Soc Clin Oncol Proc 1997, 16:152a.
4. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488-493.
5. Richards MA, Brayser S, Gregory WM, Rubens RD: Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993, 67:856-860.
6. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC: An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast. Bone 1991, 12 (suppl 1):37-42.
7. DeWald RL, Bridwell KH, Prodromas C, Rodts MF: Reconstructive spinal surgery as palliation for metastatic malignancies. Spine 1985, 10:21-26.
8. Galasko CSB. The role of the orthopaedic surgeon in the treatment of skeletal metastases. In: Bone Metastases - Diagnosis and Treatment. Edited by Rubens RD, Fogelman I. London: Springer-Verlag; 1991:207-222.
9. Hoskin PJ. Radiotherapy in the management of bone metastases. In: Bone Metastases - Diagnosis and Treatment. Edited by Rubens RD, Fogelman I. London: Springer-Verlag; 1991:207-222.
10. Lewington VJ, McEwan AJ, Ackery DM, Bayley RJ, Keeling DH, Macleod PM, et al.: A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991, 27:954-958.
11. Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA: Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 1993, 20 (suppl 2):44-48.
12. Turner JH, Claringbold BG, Heatherington EL, Sorby P, Martindal AA: A phase I study of samarium-153 ethylenediamenetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989, 7:1926-1931.
13. Dowsett M: Aromatase inhibitors come of age. Ann Oncol 1997, 8:631-632.
14. Savarase DMF, Hsieh C-C, Stewart FM: Clinical impact of chemotherapy dose escalation in patients with haematologic malignancies and solid tumours. J Clin Oncol 1997, 15:2981-2995.
15. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321:419-424.
16. Fleish H: Bisphosphonates - preclinical. In: Bisphosphonates in Bone Disease from the Laboratory to the Patient. 2nd Edition. Carnforth, UK: Parthenon; 1995:38-56.
17. Body J-J, Coleman RE, Piccart M: Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996, 22:265-287.
18. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA: Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985, 57:721-725.
19. Coleman RE: Skeletal complications of malignancy. Cancer 1997, in press.
20. Ikeda I, Miura T, Kondo I: Pyridinium cross-links as markers of bone metastases in patients with prostate cancer. Br J Urol 1996, 77:102-106.
21. Coleman RE, Purohit OP, Vinholes JJ, Zekri J: High dose pamidronate - clinical and biochemical effects in metastatic bone disease. Cancer 1997, in press.
22. Ernst DS, MacDonald RN, Paterson AHG, Jensen J, Bruera E: A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Sympt Manag 1992, 7:4-11.
23. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994, 70:554-558.
24. Clarke NW, Holbrook IB, McClure J, George NJ: Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br J Cancer 1991, 63:420-423.
25. Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, Seaman J: Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994, 5 (suppl 7):S31-S35.
26. Adami S: Bisphosphonates and prostatic carcinoma with bone metastases. In: Bisphophonate on Bones. Edited by Bijvoet OLM, Fleish HA, Canfield RE, Russell RGG. Amsterdam: Elsevier Science BV; 1995:379-394.
27. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995, 72:1289-1293.
28. Thurlimann B, Morant R, Jungi WF, Radziwill A: Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose effect study. Support Care Cancer 1994, 2:61-65.
29. Vinholes JJ, Guo C-Y, Purohit OP, Eastell R, Coleman RE: Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996, 73:1089-1095.
30. Thurlimann B, Koberle D, Engler H, Baacchus L, et al.: Predictive factors for response to bisphosphonate treatment in malignant osteolytic bone disease: who will respond to pamidronate? [Abstract]. Am Soc Clin Oncol Proc 1997, 16:52a.
31. van Holten-Verrantvoort AT, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, et al.: Palliative bone treatment in patients with bone metastases from breast cancer. J Clin Oncology 1993, 11:491-498.
32. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Double blind controlled trial of clodronate in patients with bone metastase from breast cancer. J Clin Oncol 1993, 11:59-65.
33. Conte PF, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, et al.: Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial. J Clin Oncol 1996, 14:2552-2559.
34. Hultborn R, Ryden S, Gunderson S, Holmberg E, Wallgren U-B: Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial [abstract]. Eur J Cancer 1995, 31A (suppl 5):S76.
35. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049.
36. McCloskey EV, Maclennan ICM, Drayson M, Chapman C, et al.: Effect of clodronate on progression of skeletal disease in multiple myelomatosis [abstract]. Eur J Cancer 1995, 31A (suppl 5):S162.
37. Coleman RE, Purohit OP, Black C, Vinholes J, Kanis JA, Schlosser K, et al.: Ibandronate: a well tolerated new oral bisphosphonate for the treatment of bone metastases [abstract]. Breast 1995, 4:3,236.
38. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al.: Oesophagitis associated with the use of alendronate. N Engl J Med 1996, 335:1016-1021.
39. Papapoulos SE: Treatment of established osteoporosis with bisphosphonates. In: Bisphophonate on Bones. Edited by Bijvoet OLM, Fleish HA, Canfield RE, Russell RGG. Amsterdam: Elsevier Science BV; 1995:403-416.
40. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994, 32:73-84.
41. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases with breast cancer. Bone 1996, 19:663-667.
42. Diel I, Solomayer E-F, Goerner R, Gollan CH, et al.: Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases [abstract]. Am Soc Clin Oncol Proc 1997, 16:130a.